Abstract:The zinc-containing histone deacetylase enzyme HDAC7 is emerging as an important regulator of immunometabolism and cancer. Here, we exploit a cavity in HDAC7, filled by Tyr303 in HDAC1, to derive new inhibitors. Phenacetyl hydroxamates and 2-phenylbenzoyl hydroxamates bind to Zn2+ and are 50–2700-fold more selective inhibitors of HDAC7 than HDAC1. Phenylbenzoyl hydroxamates are 30–70-fold more potent HDAC7 inhibitors than phenacetyl hydroxamates, which is attributed to the benzoyl aromatic group interacting with Phe679 and Phe738. Phthalimide capping groups, including a saccharin analogue, decrease rotational freedom and provide hydrogen bond acceptor carbonyl/sulfonamide oxygens that increase inhibitor potency, liver microsome stability, solubility, and cell activity. Despite being the most potent HDAC7 inhibitors to date, they are not selective among class IIa enzymes. These strategies may help to produce tools for interrogating HDAC7 biology related to its catalytic site.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01967?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01967</a>.Additional experimental procedures, figures and tables describing modelling for alternative docked ligand poses in HDAC7, chemical synthesis, and compound characterization (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_001.pdf">PDF</a>)Figure 3 docking pose for compound 5a (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_002.pdb">PDB</a>)Figure 4 docking pose for compound 5a (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_003.pdb">PDB</a>)Figure 4 docking pose for compound 22 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_004.pdb">PDB</a>)Figure 4 docking pose for compound 31 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_005.pdb">PDB</a>)Figure S1 docking pose for compound 5a (without water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_006.pdb">PDB</a>)Figure S1 docking pose for compound 5a (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_007.pdb">PDB</a>)Figure S2 docking pose for compound 15 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_008.pdb">PDB</a>)Figure S3 docking pose for compound 22 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_009.pdb">PDB</a>)Figure S3 docking pose for compound 30 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_010.pdb">PDB</a>)Figure S3 docking pose for compound 31 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_011.pdb">PDB</a>)SMILES strings of all compounds used for docking (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_012.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of Benzoylsulfonohydrazides As Potent Inhibitors of the Histone Acetyltransferase KAT6A.

Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, As Potent Senescence-Inducing Anti-Cancer Agents.

Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo -Active KAT6AB Inhibitor

Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer

Discovery of A Series of Hydroximic Acid Derivatives As Potent Histone Deacetylase Inhibitors

Abstract 3217: Discovery of novel inhibitors of the epigenetic regulator Kat6a histone acetyl transferase and characterization of their anti-tumor activity

<i>In silico</i> design of novel benzohydroxamate-based compounds as inhibitors of histone deacetylase 6 based on 3D-QSAR, molecular docking, and molecular dynamics simulations

Development of a histone deacetylase 6 inhibitor and its biological effects

Discovery of Meta-Sulfamoyl N-hydroxybenzamides As HDAC8 Selective Inhibitors

Identification of triazolyl KAT6 inhibitors via a templated fragment approach

Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue

HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates

Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1h-benzimidazol-5-yl}-n-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile

Development of Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides with Antitumor Activities.

Abstract PO3-26-04: Discovery of novel inhibitors of the epigenetic regulatory KAT6A histone acetyl transferase and their anti-tumor activity in breast cancer cells

Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Novel Biphenyl-Based Scaffold As Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors: Identification, Development and Pharmacological Evaluation

Syntheses and Biological Evaluation of Novel Hydroxamic Acid Derivatives Containing Purine Moiety As Histone Deacetylase Inhibitors

Design, Synthesis, and Antiproliferative Activity of Selective Histone Deacetylases 6 Inhibitors Containing a Tetrahydropyridopyrimidine Scaffold

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors